0
Letters |

Retinal Detachment and Fluoroquinolones

Petros Aristodemou, FRCOphth(Lond); Andreas C. Stylianides, MD, FRCP(Lond)
JAMA. 2012;308(3):233. doi:10.1001/jama.2012.6618.
Text Size: A A A
Published online

Extract

To the Editor: The nested case-control study by Dr Etminan and colleagues1 demonstrated an association between systemic fluoroquinolone use and episodes of treatment for retinal detachment. As the authors stated, association does not imply causation. Although the adjusted rate ratios and confidence intervals were noteworthy, several important confounding factors need to be considered.

First, the timing of fluoroquinolone use and the treatment for a retinal detachment were very short. The association was only present for current fluoroquinolone users, not for those with recent or past use. If there was a change in the vitreous that could precipitate a retinal detachment, a retinal detachment would be expected to take some time to develop. There is usually a time lag of several days or weeks between the development of a posterior vitreous detachment and the formation of retinal breaks that may lead to a retinal detachment.2 For this reason, the association between retinal detachment and fluoroquinolone use would have been expected to hold for those with recent fluoroquinolone use as well.

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

July 18, 2012
Mohammad H. Nowroozzadeh, MD
JAMA. 2012;308(3):233. doi:10.1001/jama.2012.6630.
July 18, 2012
Rajesh C. Rao, MD; Brian J. Dlouhy, MD
JAMA. 2012;308(3):233. doi:10.1001/jama.2012.6628.
July 18, 2012
Aoife C. Molloy, MD, DTMH, MRCPUK; Danny Mitry, MD, MRCSI(Ophth)
JAMA. 2012;308(3):233. doi:10.1001/jama.2012.6620.
July 18, 2012
Mahyar Etminan, PharmD, MSc; James M. Brophy, MD, PhD; David Maberley, MD, MSc
JAMA. 2012;308(3):233. doi:10.1001/jama.2012.6634.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();